A carregar...
Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders
BACKGROUND: Recombinant activated factor VII (rFVIIa, NovoSeven(®)) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX. OBJECTIVE: To review the evidence supporting the use of rFVIIa for the treatment of patients with congenital blee...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2915535/ https://ncbi.nlm.nih.gov/pubmed/20689697 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|